Alexandra Gerlach, Associate Editor

Kevin Chen, PharmD, MS, BCOP, CPP; and Amanda Cass, PharmD, BCPS, BCOP, share key insights about ROS1, non-small cell lung cancer, and the newly approved drug taletrectinib.

Pharmacists share their institution's individual, unique approaches to medication safety.

Emerging trial results reveal gedatolisib significantly enhances progression-free survival (PFS) in advanced HR+/HER2- breast cancer.

Pharmacist share actionable insights for EMR utilization and facilitation of medication safety practices.

Targeting BRD4 with BET inhibitors shows promise in reversing immune suppression by myeloid-derived suppressor cells in chronic lymphocytic leukemia.

Avatrombopag gains FDA approval for pediatric ITP treatment, offering a new oral option for managing chronic thrombocytopenia in children.

Trastuzumab deruxtecan shows promising efficacy in treating HER2-positive metastatic breast cancer with brain metastases, offering hope for challenging cases.

CDC's ACIP recommends removing thimerosal from flu vaccines, igniting debate on vaccine safety and fueling antivaccine sentiments amid public health concerns.

A Danish study confirms no link between aluminum in childhood vaccines and chronic diseases, reinforcing vaccine safety amid rising skepticism.

Eugene Przespolewski, PharmD, BCOP, DPLA, shares insights from his presentation at the 2025 OPC meeting in Austin, Texas.

The advisory committee cited concerns around ocular toxicity and overall tolerability, raising serious questions about the drug's benefit-risk profile ahead of its scheduled Prescription Drug User Fee Act action date on July 23, 2025.

Pharmacists play a vital role in translating global health news into actionable knowledge for their communities.

Research reveals HER2-negative breast cancer shows higher pCR rates than HER2-low, influencing neoadjuvant chemotherapy strategies for early-stage patients.

Research reveals that higher BMI in women with cardiovascular disease significantly increases breast cancer risk, highlighting the need for targeted prevention strategies.

An adjusted analysis of the ALPINE and ASCEND trials revealed a statistically significant progression-free survival advantage for zanubrutinib.

The agent, Kirsty, represents a more affordable alternative to Novolog.

The data showed patients with relapsed or refractory multiple myeloma achieved a 73% overall response rate.

Combination therapy with trastuzumab emtansine and trastuzumab significantly enhances survival rates in HER2-positive early breast cancer, outperforming trastuzumab alone.

Dalpiciclib combined with endocrine therapy significantly enhances progression-free survival in HR+/HER2– breast cancer, as shown in the DAWNA-A trial.

States have expanded access to over-the-counter ivermectin, raising concerns among health experts about safety, misinformation, and self-medication risks.

Obesity and high-fat diets enhance the aggressiveness of triple-negative breast cancer through exosome-mediated mechanisms, revealing new therapeutic targets.

New research highlights the lower infection risk with zanubrutinib compared with venetoclax in CLL/SLL treatment, offering safer options for patients.

New data reveal isatuximab-based therapy achieves high MRD-negativity rates in newly diagnosed multiple myeloma.

Research reveals that combining radiotherapy or immune-modulating drugs with CDK4/6 inhibitors enhances treatment efficacy in HR+/HER2– breast cancer.

Funding cuts to public health agencies threaten to worsen chronic diseases and ignite infectious disease outbreaks, straining health care systems nationwide.

LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA, discusses the new outpatient transplant program at Atrium Health Wake Forest Baptist in North Carolina.

Research reveals a link between estrogen plus progestin hormone therapy and increased breast cancer risk in young women, urging personalized treatment approaches.

LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA, discusses the new outpatient transplant program at Atrium Health Wake Forest Baptist in North Carolina.

CARTITUDE-1 trial reveals cilta-cel's potential in achieving long-term remission for relapsed/refractory multiple myeloma, sparking discussions on curative possibilities.

The data revealed that only 75% of patients receive HER2-targeting therapies.